Enveloped virus particles

Enveloped virus particles are infectious agents characterized by a nucleocapsid surrounded by a lipid bilayer membrane, which is typically acquired from the host cell's plasma or internal membranes during the process of viral budding (Source: NIH/NCBI). This lipid envelope is embedded with viral-encoded glycoproteins that are essential for the virus to recognize, attach to, and fuse with specific receptors on host cell membranes, thereby initiating the infection cycle (Source: Nature Education). Because the integrity of the envelope and the function of its surface proteins are vital for infectivity, they represent primary targets for antiviral drug development and vaccine design (Source: PubMed). Therapeutic strategies targeting enveloped viruses include the use of fusion inhibitors like enfuvirtide, which prevents the conformational changes in viral proteins required for membrane merging, and monoclonal antibodies like palivizumab that neutralize the virus by blocking surface glycoproteins (Source: DrugBank). However, the classification of "Enveloped virus particles" as a single therapeutic target is considered too broad for structured drug discovery, as most effective therapies are highly specific to the unique proteins of individual virus families, such as HIV, Influenza, or Coronaviruses (Source: StatPearls). Furthermore, while the lipid envelope makes these viruses susceptible to detergents and certain lipid-disrupting agents, the systemic use of such agents is limited by the potential for significant toxicity to the host's own cellular membranes (Source: Wikipedia).

Other names

Enveloped virusesViral envelopeLipid-enveloped virions

Inhibition of viral-host membrane fusion, blocking of viral attachment proteins, or disruption of the viral lipid envelope.